Antigen identification strategies and preclinical evaluation models for advancing tuberculosis vaccine development
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Antigen identification strategies and preclinical evaluation models for advancing tuberculosis vaccine development ; volume:9 ; number:1 ; day:9 ; month:3 ; year:2024 ; pages:1-21 ; date:12.2024
npj vaccines ; 9, Heft 1 (9.3.2024), 1-21, 12.2024
- Creator
-
Chugh, Saurabh
Bahal, Ritika Kar
Dhiman, Rohan
Singh, Ramandeep
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41541-024-00834-y
- URN
-
urn:nbn:de:101:1-2405122116258.410155420606
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:50 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chugh, Saurabh
- Bahal, Ritika Kar
- Dhiman, Rohan
- Singh, Ramandeep
- SpringerLink (Online service)
Other Objects (12)
Design of liposomes for the delivery of antigens for a vaccine against tuberculosis
Advancing preclinical cancer models to assess clinically relevant outcomes
Vaccine design via antigen reorientation
Advancing cancer immunotherapy: from innovative preclinical models to clinical insights
Mycobacterium tuberculosis Rv0679c protein sequences involved in host-cell infection: Potential TB vaccine candidate antigen
Vaccine against tuberculosis: what’s new?
P19-36. Preclinical study of CombiHIVvac vaccine
Advancing preclinical models of psychiatric disorders with human brain organoid cultures
Harnessing synthetic biology for advancing RNA therapeutics and vaccine design
Microvascularized tumor organoids-on-chips: advancing preclinical drug screening with pathophysiological relevance
Preclinical Safety Evaluation: Acute and Repeated-Dose Toxicity of a New Intranasal Recombinant Vector Vaccine TB/FLU-04L Against Tuberculosis
Immunogenicity of infectious pathogens and vaccine antigens
Design of liposomes for the delivery of antigens for a vaccine against tuberculosis
Advancing preclinical cancer models to assess clinically relevant outcomes
Vaccine design via antigen reorientation
Advancing cancer immunotherapy: from innovative preclinical models to clinical insights
Mycobacterium tuberculosis Rv0679c protein sequences involved in host-cell infection: Potential TB vaccine candidate antigen
Vaccine against tuberculosis: what’s new?
P19-36. Preclinical study of CombiHIVvac vaccine
Advancing preclinical models of psychiatric disorders with human brain organoid cultures
Harnessing synthetic biology for advancing RNA therapeutics and vaccine design
Microvascularized tumor organoids-on-chips: advancing preclinical drug screening with pathophysiological relevance
Preclinical Safety Evaluation: Acute and Repeated-Dose Toxicity of a New Intranasal Recombinant Vector Vaccine TB/FLU-04L Against Tuberculosis
Immunogenicity of infectious pathogens and vaccine antigens
Design of liposomes for the delivery of antigens for a vaccine against tuberculosis
Advancing preclinical cancer models to assess clinically relevant outcomes
Vaccine design via antigen reorientation
Advancing cancer immunotherapy: from innovative preclinical models to clinical insights
Mycobacterium tuberculosis Rv0679c protein sequences involved in host-cell infection: Potential TB vaccine candidate antigen
Vaccine against tuberculosis: what’s new?
P19-36. Preclinical study of CombiHIVvac vaccine
Advancing preclinical models of psychiatric disorders with human brain organoid cultures
Harnessing synthetic biology for advancing RNA therapeutics and vaccine design
Microvascularized tumor organoids-on-chips: advancing preclinical drug screening with pathophysiological relevance
Preclinical Safety Evaluation: Acute and Repeated-Dose Toxicity of a New Intranasal Recombinant Vector Vaccine TB/FLU-04L Against Tuberculosis